NEU1 and COVID-19: NEU1 has been proposed as a potential therapeutic target for COVID-19, and against viral pathogens in future coronavirus pandemics, on the basis that NEU1 inhibitors can limit SARS-CoV-2 replication in COVID-19 patients [114,115].